Back to Treatments

Treatment

Nirmatrelvir/Ritonavir (Paxlovid)

2
Conditions
54
Trials
23K
Participants
63%
Average Safety

Condition Evidence

COVID-19

45 trials · 15K participants

85% effectiveness · 60% safety

Long COVID

9 trials · 7,500 participants

50% effectiveness · 65% safety
Nirmatrelvir/Ritonavir (Paxlovid) | DFDA